Adoption of accelerated glucocorticoid tapering and its clinical consequences in ANCA-associated vasculitis: the J-CANVAS registry

Abstract Glucocorticoid tapering in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis has been accelerated, whereas avacopan offers an alternative despite trial retraction. However, whether these regimens are safely implemented in routine practice remains uncertain. We analysed 774 induction episodes of microscopic polyangiitis or granulomatosis with polyangiitis from the J-CANVAS registry (2017–2023), classifying tapering speed at week 8 according to whether the dose was at or below the PEXIVAS reduced-dose target, with overlap weighting on 15 covariates; the primary outcome was 52-week relapse. The faster-taper group received 1448 mg less cumulative prednisolone over weeks 0–24 than the slower-taper group, with a trend toward a higher risk of relapse (hazard ratio, 1.53; 95% confidence interval, 0.90–2.58) driven by minor relapses. Over weeks 8–24, avacopan spared no more glucocorticoid than faster tapering without the drug (649 versus 691 mg less than slower tapering). Attainment of the week-8 target increased from 14.0% to 43.5%, yet only 15.3% met the standard target by week 20, and the between-centre variation was substantial (median odds ratio, 2.66). Faster tapering has been adopted in routine care and has substantially reduced exposure, with any excess relapse confined to minor events. No increase in major relapses or deaths was detected. Whether the exchange is worthwhile is a clinical judgement.

Authors

Institutions

Publication Details

Journal
Clinical and Experimental Medicine
Published
2026-11-14
DOI
https://doi.org/10.1007/s10238-026-02392-0
Primary Topic
Vasculitis and related conditions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Adoption of accelerated glucocorticoid tapering and its clinical consequences in ANCA-associated vasculitis: the J-CANVAS registry

Naoto Azuma, Ryo Nishioka, Hiroko Sato, Yutaka Kawahito et al.
Clinical and Experimental Medicine
Vasculitis and related conditions
article

Adoption of accelerated glucocorticoid tapering and its clinical consequences in ANCA-associated vasculitis: the J-CANVAS registry

Naoto Azuma, Ryo Nishioka, Hiroko Sato, Yutaka Kawahito, Toshiko Ito‐Ihara, Shoichi Fukui, Tomoaki Takata, Yasuhiro Shimojima, Naohisa Tsuchida, Tohru Takeuchi, 知史 大村, Yuji Kukida, Daiki Nakagomi, Naoya Kondo, Yoshia Miyawaki, Yusho Ishii, Toshihiko Takada, Nobuyuki Yajima, Tsuyoshi Shirai, Ryo Yanai, Shintaro Hirata, Yoshiyuki Abe, Atsushi Nomura, Takafumi Ito, Kentaro Mori, Hiroshi Fujii, Koji Endo, Mayuko Moriyama, Ayuko Takatani, Yusuke Matsuo, Hirosuke Takagi, Takashi Kida, Ryota Okazaki, Takashi Kawaguchi, Isao Matsumoto, Hiroaki Dobashi, Makoto Wada, Naoho Takizawa
article en

Abstract

Abstract Glucocorticoid tapering in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis has been accelerated, whereas avacopan offers an alternative despite trial retraction. However, whether these regimens are safely implemented in routine practice remains uncertain. We analysed 774 induction episodes of microscopic polyangiitis or granulomatosis with polyangiitis from the J-CANVAS registry (2017–2023), classifying tapering speed at week 8 according to whether the dose was at or below the PEXIVAS reduced-dose target, with overlap weighting on 15 covariates; the primary outcome was 52-week relapse. The faster-taper group received 1448 mg less cumulative prednisolone over weeks 0–24 than the slower-taper group, with a trend toward a higher risk of relapse (hazard ratio, 1.53; 95% confidence interval, 0.90–2.58) driven by minor relapses. Over weeks 8–24, avacopan spared no more glucocorticoid than faster tapering without the drug (649 versus 691 mg less than slower tapering). Attainment of the week-8 target increased from 14.0% to 43.5%, yet only 15.3% met the standard target by week 20, and the between-centre variation was substantial (median odds ratio, 2.66). Faster tapering has been adopted in routine care and has substantially reduced exposure, with any excess relapse confined to minor events. No increase in major relapses or deaths was detected. Whether the exchange is worthwhile is a clinical judgement.

Clinical and Experimental Medicine
Kanazawa University (JP), SHOWA Medical University (JP), Tokyo Medical and Dental University (JP), Fukushima Medical University (JP), Hyogo Medical University (JP), Shinshu University (JP), University of Tsukuba (JP), Tokyo University of Pharmacy and Life Sciences (JP), Okayama University (JP), Shimane University (JP), Tohoku University (JP), Kagawa University (JP), Osaka Medical and Pharmaceutical University (JP), Hokkaido University (JP), Kyoto University (JP), University of Shimane (JP), Juntendo University (JP), Kyoto Prefectural University of Medicine (JP), St. Luke's International Hospital (JP), Chubu Rosai Hospital (JP), Tohoku University Hospital (JP), University of Yamanashi Hospital (JP), Kagoshima University Hospital (JP), Hiroshima University Hospital (JP), Kyoto first Red Cross hospital (JP), University Hospital Kyoto Prefectural University of Medicine (JP), Shinshu University Hospital (JP), Teikyo University Chiba Medical Center (JP), Kagawa University Hospital (JP), Kyoto Katsura Hospital (JP), Japanese Red Cross Society Kyoto Daini Hospital (JP), Nagasaki University (JP), Institute of Science Tokyo (JP), Sasebo Chuo Hospital (JP), Tokyo Kyosai Hospital (JP), Tottori University (JP), University of Yamanashi (JP)
Vasculitis and related conditions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon